Amy Fowler

Dr. Amy Fowler


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SDSara W. Dyrstad
Sara W. Dyrstad
YYYan Yan
Yan Yan
AFAmy Fowler
Amy Fowler
GCGraham A Colditz
Graham A Colditz

8 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
CSChristina M. Scribano
Christina M. Scribano
JWJun Wan
Jun Wan
KEKarla Esbona
Karla Esbona
JTJohn B. Tucker
John B. Tucker
ALAmber Lasek
Amber Lasek
BWBeth A. Weaver
Beth A. Weaver
Paclitaxel cytotoxicity in breast tumors depends on multipolar spindle maintenance and preexisting chromosomal instability.

1 January 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
AFAmy Fowler
Amy Fowler
RSRoberta M Strigel
Roberta M Strigel

1 March 2014 in Current Problems in Diagnostic Radiology
Verified
Journal Article
Closed access
SDSara W. Dyrstad
Sara W. Dyrstad
AFAmy Fowler
Amy Fowler
CJClint E. Jokerst
Clint E. Jokerst
JBJonathan C. Baker
Jonathan C. Baker
THTravis J. Hillen
Travis J. Hillen
CMChristine Menias
Christine Menias

1 February 2016 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
AFAmy Fowler
Amy Fowler
ACAmy S. Clark
Amy S. Clark
JKJohn A. Katzenellenbogen
John A. Katzenellenbogen
HLHannah M. Linden
Hannah M. Linden
FDFarrokh Dehdashti
Farrokh Dehdashti
Estrogen receptor alpha (ERα) and progesterone receptor (PR) are important steroid hormone receptor biomarkers used to determine prognosis and to predict benefit from endocrine therapies for breast cancer patients. Receptor expression is routinely measured in biopsy specimens using immunohistochemistry, although such testing can be challenging, particularly in the setting of metastatic disease. ERα and PR can be quantitatively assayed noninvasively with PET. This approach provides the opportunity to assess receptor expression and function in real time, within the entire tumor, and across distant sites of metastatic disease. This article reviews the current evidence of ERα and PR PET imaging as predictive and early-response biomarkers for endocrine therapy.

1 October 2023 in RadioGraphics
Verified
Journal Article
Closed access
MPMolly S. Peterson
Molly S. Peterson
AGAlison R. Gegios
Alison R. Gegios
MEMai A. Elezaby
Mai A. Elezaby
LSLonie R. Salkowski
Lonie R. Salkowski
RWRyan W. Woods
Ryan W. Woods
AFAmy Fowler
Amy Fowler
Physiologic changes that occur in the breast during pregnancy and lactation create challenges for breast cancer screening and diagnosis. Despite these challenges, imaging evaluation should not be deferred, because delayed diagnosis of pregnancy-associated breast cancer contributes to poor outcomes. Both screening and diagnostic imaging can be safely performed using protocols based on age, breast cancer risk, and whether the patient is pregnant or lactating. US is the preferred initial imaging modality for the evaluation of clinical symptoms in pregnant women, followed by mammography if the US findings are suspicious for malignancy or do not show the cause of the clinical symptom. Breast MRI is not recommended during pregnancy because of the use of intravenous gadolinium-based contrast agents. Diagnostic imaging for lactating women is the same as that for nonpregnant nonlactating individuals, beginning with US for patients younger than 30 years old and mammography followed by US for patients aged 30 years and older. MRI can be performed for high-risk screening and local-regional staging in lactating women. The radiologist may encounter a wide variety of breast abnormalities, some specific to pregnancy and lactation, including normal physiologic changes, benign disorders, and malignant neoplasms. Although most masses encountered are benign, biopsy should be performed if the imaging characteristics are suspicious for cancer or if the finding does not resolve after a short period of clinical follow-up. Knowledge of the expected imaging appearance of physiologic changes and common benign conditions of pregnancy and lactation is critical for differentiating these findings from pregnancy-associated breast cancer. ©RSNA, 2023 Online supplemental material is available for this article. Quiz questions for this article are available through the Online Learning Center.